ARTICLE | Clinical News

PRO 140: Ph IIb/III started

December 13, 2016 10:12 PM UTC

CytoDyn began an open-label, U.S. Phase IIb/III trial to evaluate 350 mg subcutaneous PRO 140 once weekly as monotherapy for 48 weeks in about 300 patients with CCR5-tropic HIV-1 infection who are cli...

BCIQ Company Profiles

CytoDyn Inc.